NCT03951259View on ClinicalTrials.gov

Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

October 13, 2023

Study Completion Date

October 19, 2023

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

SM934

In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

DRUG

Placebos

The placebo pills are made identical to the investigating SM934 in appearance.

Trial Locations (1)

200001

Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai

All Listed Sponsors
collaborator

Jiangsu ZuoYou Medicine Co., Ltd.

UNKNOWN

lead

RenJi Hospital

OTHER

NCT03951259 - Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter